Table 1.

Demographic characteristics of women with endometrial or ovarian cancer and women in the respective subcohort from a case-cohort study within B~FIT.

	Endometrial Cases (n=65)	Subcohort (n=345)	Ovarian Cases (n=67)	Subcohort (n=413)
Characteristic	n (%)	n (%)	n (%)	n (%)
Age
<65	17 (26.2)	135 (39.1)	21 (31.3)	165 (40.0)
≥65	48 (73.9)	210 (60.9)	46 (68.7)	248 (60.1)
Race/ethnicity
Non-Hispanic White	64 (98.5)	329 (95.4)	65 (97.0)	394 (95.4)
Other	1 (1.5)	16 (4.6)	2 (3.0)	19 (4.6)
Group
Screened	58 (89.2)	252 (73.0)	57 (85.1)	308 (74.6)
FIT	6 (9.2)	73 (21.2)	10 (14.9)	83 (20.1)
FIT + FLEX	1 (1.5)	20 (5.8)	0 (0.0)	22 (5.3)
BMI (kg/m2)
<25.0	19 (29.2)	157 (45.5)	25 (37.3)	176 (42.6)
25.0–29.9	19 (29.2)	108 (31.3)	24 (35.8)	132 (32.0)
>30.0	25 (38.5)	79 (22.9)	18 (26.9)	102 (24.7)
Missing	2 (3.1)	1 (0.3)	0 (0.0)	3 (0.7)
Parity
Nulliparous	13 (20.0)	33 (9.6)	8 (11.9)	40 (9.7)
1 birth	9 (13.9)	41 (11.9)	7 (10.5)	45 (10.9)
≥2 births	43 (66.2)	271 (78.6)	52 (77.6)	328 (79.4)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Oral contraceptive use
Never	38 (58.5)	160 (46.4)	25 (37.3)	195 (47.2)
Ever	9 (13.9)	51 (14.8)	7 (10.5)	59 (14.3)
Missing	18 (27.7)	134 (38.8)	35 (52.2)	159 (38.5)
Years postmenopausal at blood draw
<10	6 (9.2)	44 (12.8)	7 (10.5)	44 (10.7)
10–19	35 (53.9)	150 (43.5)	18 (26.9)	163 (39.5)
20+	22 (33.9)	149 (43.2)	41 (61.2)	203 (49.2)
Missing	2 (3.1)	2 (0.6)	1 (1.5)	3 (0.7)
Duration of prior estrogen only (endometrial analysis) or estrogen and/or progestin (ovarian analysis) menopausal hormone therapy use
Never or <1 year	48 (73.9)	279 (80.9)	51 (76.1)	326 (78.9)
1–4 years	7 (10.8)	44 (12.8)	7 (10.5)	53 (12.8)
5–9 years	4 (6.2)	12 (3.5)	4 (6.0)	20 (4.8)
≥10 years	6 (9.2)	10 (2.9)	4 (6.0)	14 (3.4)
Missing	0 (0.0)	0 (0.0)	1 (1.5)	0 (0.0)